(1 - 14 von 16
)
Ralph Schiess, CEO ProteoMediX AG
www.finanznachrichten.de
Ralph Schiess, CEO ProteoMediX AG. (Foto: de Vigier Stiftung) von Patrick Gunti Moneycab: Herr Schiess, die ProteoMediX AG hat von der de Vigier-Stiftung den am ...
ProteoMediX receives ISO :2012 Certification › BIO-TECHNOPARK®...
www.bio-technopark.ch
ProteoMediX AG, a diagnostic company producing non-invasive in vitro diagnostic assays for prostate cancer diagnosis, has been awarded ISO ...
Analyse bestätigt Wirksamkeit von Proclarix - News Limmatstadt
www.limmatstadt.ch
Schlieren ZH - Ein medizinischer Fachbericht bestätigt die Wirksamkeit eines Tests der Schlieremer Firma Proteomedix. Diese hat Proclarix als blutbasierten...
Vers une médecine personnalisée grâce au diagnostic - The Ark
www.theark.ch
Cancer-genetics guided biomarker discovery and validation. Dr. Ralph Schiess, Proteomedix, Zurich. 11h00, Pause café. Exposition de posters des étudiants de ...
Promoting innovation in Valais - BioArk
www.bioark.ch
Dr. Michael Schumacher from IIG / HES-SO Valais-Wallis. 10h30, Cancer-genetics guided biomarker discovery and validation. Dr. Ralph Schiess, Proteomedix, ...
ProteoMediX Raises CHF 3.2M (€2.6M) in Financing | Technology ...
www.technologynetworks.com
Dr. Ralph Schiess, CEO and co-founder commented: “We are delighted to have received this strong support from investors. The funds will ...
ProteoMediX Raises CHF 5.2 million in Financing Round
www.startupticker.ch
Dr. Ralph Schiess, CEO commented: “We are very pleased with the continuous financial support we receive. This reflects the continuous ...
Profiling Looms Large in Cancer Research
www.genengnews.com
Academics take leading role in charge to find better ways to discover and validate oncologic biomarkers.
Studie zeigt Wirksamkeit von ProteoMediX-Test › BIO-TECHNOPARK®...
www.bio-technopark.ch
Schlieren ZH - Das Schlieremer Unternehmen ProteoMediX entwickelt einen neuen Bluttest, der die Erkennung von Prostatakrebs ...
ProteoMediX Raises CHF 1.0 million in Extended Series B Financing
www.startupticker.ch
Dr. Ralph Schiess, CEO and co-founder commented: “We are delighted to have received additional funds that will enable us to gather ...
SRF berichtet über ProteoMediX-Test › BIO-TECHNOPARK® Schlieren-Zürich
www.bio-technopark.ch
Schlieren ZH – Das Schlieremer Unternehmen ProteoMediX hat einen Bluttest für die Erkennung von Prostatakrebs entwickelt.
Team:ETH Zurich/Practices/Business igem.org2015.igem.org › Team:ETH_Zurich
2015.igem.org
In summary, we retained the following from Ralph Schiess' answers: Bringing our device to market would probably cost around $20 Million. In general you can ...
Vers une médecine personnalisée grâce au diagnostic - BioArk
www.bioark.ch
Dr. Ralph Schiess, Proteomedix, Zurich. 11h00, Pause café. Exposition de posters des étudiants de la HES-SO Valais-Wallis. SESSION 2
sortiert nach Relevanz / Datum